A Study of LY3867070 in Healthy Participants

This study is looking for healthy volunteers to help us understand LY3867070. We want to see how well your body tolerates LY3867070 and what side effects might occur. Participants will receive either LY3867070 or a placebo (an inactive substance) by mouth. We will also take blood samples to learn how your body handles the drug and what effects it has. The main goals are to track any side effects that happen during the study, especially those considered serious. We are looking for healthy individuals between 18 and 65 years old, who weigh at least 45 kg (about 99 lbs) and have a body mass index (BMI) between 18 and 32. The study aims to enroll 196 participants, but its current status is unclear.

Study design: This is an interventional study involving 196 planned participants. Participants will be given either LY3867070 or a placebo orally.
What's involved: Not specified in the trial record.
Compensation: Not stated in the trial record.
Follow-up: Participants will be monitored for adverse events from baseline up to approximately Week 7 after receiving the study drug.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

A Study of LY3867070 in Healthy Participants

Recruiting

PHASE1Ages 18–65InterventionalBasic science

Eli Lilly and Company

~196 participants

Updated 2026-06-03 on ClinicalTrials.gov

What's tested:LY3867070Placebo

At a glance

Recruiting sites

2 of 2 listed sites are recruiting right now

RecruitingSuspended, closed, or not yet open

What they're measuring

Number of Participants with One or More Treatment Emergent Adverse Events (TEAEs) Considered by the Investigator to be Related to Study Drug Administration

Measured over Baseline up to Approximately Week 7

+2 more outcomes measured

Conditions

Healthy

Where it's being run

2 sites across 2 states

California1

Texas1

Study leadership

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 8 AM - 8 PM Eastern time (UTC/GMT - 5 hours, EST) · STUDY_DIRECTOR · Eli Lilly and Company

Who to contact

Trial questions or participation questions: 1-877-CTLILLY (1-877-285-4559) or

[email protected]

1-317-615-4559

Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime

Eligibility criteria

Inclusion

Are overtly healthy as determined by medical evaluation

Part C of the study includes only Japanese and Chinese participants

Have a body weight greater than or equal to 45 kilogram (kg) and also body mass index 18 to 32 kilogram per square meter (kg/m²) inclusive

Exclusion

Have a history or presence of multiple or severe allergies, anaphylactic reaction to prescription or nonprescription drugs, or history of significant atopy

Have a significant history or current thyroid disease

Have a significant history of or current psychiatric disorders, rheumatologic, cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrine (such as Cushing syndrome and hyperaldosteronism), hematological, or neurological disorders

Are smokers (including electronic cigarettes) within 6 months prior to screening and unwilling to refrain from smoking for the duration of the study.

Unwilling to undergo skin biopsies (for Part B only)

Are unwilling to have body hair cut or shaved in cases where hair, in the investigator's opinion, could interfere with noninvasive skin patch

What this trial measures

Number of Participants with One or More Treatment Emergent Adverse Events (TEAEs) Considered by the Investigator to be Related to Study Drug AdministrationBaseline up to Approximately Week 7
A summary of TEAEs regardless of causality, will be reported in the Reported Adverse Events module
Number of Participants with One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug AdministrationBaseline up to Approximately Week 7
A summary of SAEs regardless of causality, will be reported in the Reported Adverse Events module
Number of Participants with One or More Adverse Event(s) (AEs) Considered by the Investigator to be Related to Study Drug AdministrationBaseline up to Approximately Week 7
A summary of AEs regardless of causality, will be reported in the Reported Adverse Events module

Trialytics